118 related articles for article (PubMed ID: 28141936)
1. The value of survival gains in myelodysplastic syndromes.
MacEwan JP; Yin W; Kaura S; Khan ZM
Am J Manag Care; 2017 Jan; 23(1):e10-e15. PubMed ID: 28141936
[TBL] [Abstract][Full Text] [Related]
2. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
[TBL] [Abstract][Full Text] [Related]
3. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
De Roos AJ; Deeg HJ; Davis S
Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
[TBL] [Abstract][Full Text] [Related]
4. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
5. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes: incidence and survival in the United States.
Ma X; Does M; Raza A; Mayne ST
Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
[TBL] [Abstract][Full Text] [Related]
7. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
9. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.
Fletcher SA; Cronin AM; Zeidan AM; Odejide OO; Gore SD; Davidoff AJ; Steensma DP; Abel GA
Cancer; 2016 Apr; 122(8):1209-15. PubMed ID: 26914833
[TBL] [Abstract][Full Text] [Related]
10. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
11. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013.
Al-Kali A; Zblewski D; Foran JM; Patnaik MS; Larrabee BR; Gangat N; Begna KH; Elliott MA; Hogan WJ; Tefferi A; Litzow MR; Go RS
Mayo Clin Proc; 2019 Aug; 94(8):1467-1474. PubMed ID: 31378228
[TBL] [Abstract][Full Text] [Related]
13. Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.
Díez Campelo M; Sánchez-Barba M; de Soria VG; Martino R; Sanz G; Insunza A; Bernal T; Duarte R; Amigo ML; Xicoy B; Tormo M; Iniesta F; Bailén A; Benlloch L; Córdoba I; López-Villar O; Del Cañizo MC;
Leuk Res; 2014 Oct; 38(10):1199-206. PubMed ID: 25139847
[TBL] [Abstract][Full Text] [Related]
14. Therapy-related myelodysplastic syndrome following primary breast cancer.
Malmgren JA; Calip GS; Pyott SM; Atwood MK; Kaplan HG
Leuk Res; 2016 Aug; 47():178-84. PubMed ID: 27414978
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.
Komrokji RS; Matacia-Murphy GM; Al Ali NH; Beg MS; Safa MM; Rollison DE; List AF
Leuk Res; 2010 Jan; 34(1):59-62. PubMed ID: 19368972
[TBL] [Abstract][Full Text] [Related]
17. Health care utilization and mortality among elderly patients with myelodysplastic syndromes.
Lindquist KJ; Danese MD; Mikhael J; Knopf KB; Griffiths RI
Ann Oncol; 2011 May; 22(5):1181-1188. PubMed ID: 21041376
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Rollison DE; Howlader N; Smith MT; Strom SS; Merritt WD; Ries LA; Edwards BK; List AF
Blood; 2008 Jul; 112(1):45-52. PubMed ID: 18443215
[TBL] [Abstract][Full Text] [Related]
19. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Fega KR; Abel GA; Motyckova G; Sherman AE; DeAngelo DJ; Steensma DP; Galinsky I; Wadleigh M; Stone RM; Driver JA
J Geriatr Oncol; 2015 Jul; 6(4):288-98. PubMed ID: 26073533
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
Craig BM; Rollison DE; List AF; Cogle CR
Leuk Res; 2011 Nov; 35(11):1453-6. PubMed ID: 21851978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
